ArticleJournal of neurochemistry2026
The Kappa Free Light Chains Index in Multiple Sclerosis: From Emerging Evidence to Clinical Application.
Article in Journal of neurochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The kappa free light chain (KFLC) index is a promising biomarker for detecting intrathecal immunoglobulin synthesis in multiple sclerosis (MS), offering a quantitative and automated alternative to oligoclonal bands (OCBs). However, its use in clinical practice is limited by heterogeneous thresholds and a lack of standardized diagnostic algorithms. Objective to develop and validate a biological diagnostic algorithm for MS that fully integrates the KFLC-index alongside current recommended CSF biomarkers, particularly CSF-restricted OCBs. We conducted a prospective, monocentric study including 198 patients undergoing lumbar puncture for suspected neurological disease. Patients were classified as having MS (including CIS/RIS) or non-inflammatory neurological disorders. Paired cerebrospinal fluid and serum KFLC and LFLC were quantified using a turbidimetric assay (Optilite, The Binding Site). Diagnostic performance was assessed by ROC analysis. A diagnostic algorithm was developed and validated in an independent cohort. In the derivation cohort (n = 80), the KFLC-index showed excellent accuracy (AUC = 0.93). An optimal threshold of 20.27 provided 80.6% sensitivity and 100% specificity. A lower threshold of 3 increased sensitivity (96.8%) but reduced specificity (26.5%). Application of the diagnostic algorithm to the replication cohort (n = 70) confirmed the absence of false positive and false negative results for threshold values. Systematic OCBs testing enhanced interpretation in intermediate KFLC-index ranges (3-20). The algorithm's performance was consistent with previously published thresholds. The KFLC-index is a robust biomarker for MS diagnosis. Integration into a tiered algorithm offers excellent diagnostic performance, though local validation remains essential before broad clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.